Open AccessBreast Conservation Therapy for Invasive Breast Cancer in Ashkenazi Women With BRCA Gene Founder Mutations
Author(s) -
Mark E. Robson,
Deborah Levin,
Mark G. Federici,
Jaya M. Satagopan,
Faina Bogolminy,
Alexandra S. Heerdt,
Patrick I. Borgen,
Beryl McCormick,
Clifford A. Hudis,
Larry Norton,
Jeff Boyd,
Kenneth Offit
Publication year - 1999
Publication title -
journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/91.24.2112
Subject(s) - breast cancer , medicine , oncology , cancer , germline mutation , brca mutation , germline , gynecology , mutation , gene , genetics , biology
Germline mutations in the BRCA1 and BRCA2 genes are associated with an increased risk of breast cancer. Whether women with breast cancer who have inherited mutations in these genes have a different outcome after breast conservation therapy than women with "sporadic" cancer is unresolved. Consequently, we compared the outcomes after breast conservation therapy in Ashkenazi women with or without germline mutations in BRCA1 and/or BRCA2 (hereafter called BRCA).